Supernus Pharmaceuticals
SUPN
327 hedge funds and large institutions have $3.01B invested in Supernus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 117 increasing their positions, 117 reducing their positions, and 40 closing their positions.
6% more capital invested
Capital invested by funds: $2.84B → $3.01B (+$168M)
1.49% more ownership
Funds ownership: 99.62% → 101.11% (+1.5%)
5% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 40
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 117
2% less funds holding
Funds holding: 333 → 327 (-6)
41% less call options, than puts
Call options by funds: $3.42M | Put options by funds: $5.84M
Top Buyers
Top Sellers
SUPN Hedge Fund Activity: Q1 2026 in Review
327 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2026, worth a combined $3.01B — up 5.9% from $2.84B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SUPN positions and 40 closed out — a net gain of 2 holders — while 117 added to existing stakes and 117 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $53M. The largest seller was Point72 Asset Management, cutting an estimated $48.2M.
- 327 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2026, down from 333 in Q4 2025.
- Funds reported $3.01B of Supernus Pharmaceuticals stock for Q1 2026, up 5.9% quarter-over-quarter.
- 42 funds opened new Supernus Pharmaceuticals positions in Q1 2026 and 40 closed out, a net change of +2 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $53M added.
- The largest Supernus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $48.2M sold.
Based on aggregated 13F filings for Q1 2026.